搜索结果111-120 的 10161 / ◈애인처럼◈사우동오피∋ YEOTOP1.COM ∈ 사우동오피ⅳ사우동안마や사우동립카페➬사우동OP✸사우동휴게텔➵사우동키스방

1. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

2. 神经科- 临床试验- 妙佑医疗国际

   To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect.

3. 2 型糖尿病 - 医生与科室 - 妙佑医疗国际

   高血糖水平是糖尿病的主要问题。了解可降低风险的生活方式改变以及2 型糖尿病的治疗方法。

4. 神经科- 临床试验- 妙佑医疗国际

   This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may ...

5. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

6. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

7. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

8. 神经科- 临床试验- 妙佑医疗国际

   To establish a repository of DNA samples collected prospectively from patients with inherited myopathies of unknown molecular and/or biochemical defect.

9. 神经科- 临床试验- 妙佑医疗国际

   Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In ...

10. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...